Business
Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors
Oakville, Ontario--(Newsfile Corp. - December 3, 2019) - Cardiol Therapeutics Inc. ( TSX: CRDL...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of DirectorsOakville, Ontario--(Newsfile Corp. - December 3, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart disease, is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately. Mr. Stott is the former Scientific Affairs Director, International and R&D Operations Director for GW Pharmaceuticals plc (\"GW Pharma\"), a world leader in the development of cannabinoid therapeutics and the company which created Epidiolex®, the first FDA-approved cannabidiol therapy for use as an orphan drug in rare forms of pediatric epilepsy. Currently Chief Operating Officer of Alinova Biosciences Ltd, Mr. Stott is a veteran of the pharmaceutical and biotech industries, having almost 30 years' experience in pre-clinical and clinical development, with specific expertise in the development of cannabinoid-based medicines, and 19 years' experience in the field. As R&D Operations Director at GW Pharma for over 16 years, Colin was a key player in the development of their discovery and development pipeline, and was closely involved in the Marketing Authorization Application submission and approval of Sativex® and the New Drug Application submission of Epidiolex®, which was approved by the U.S. Food and Drug Administration in June 2018. More recently, as Scientific Affairs Director, International, he was part of the Medical Affairs team responsible for the preparation of the international launch of Epidiolex®. \"I am pleased to welcome Colin Stott to our Board of Directors,\" stated David Elsley, President and CEO of Cardiol Therapeutics. \"Mr. Stott brings unparalleled experience in the biopharmaceutical industry, particularly with cannabinoid medicines, regulatory approvals, and product launches. Colin's involvement in the successful approval of Epidiolex® in the U.S. as an orphan drug will also prove invaluable to Cardiol as we advance our plans to develop CardiolRx™100 pharmaceutical cannabidiol as a potential orphan drug for the treatment of acute myocarditis.\" CardiolRx™100, a 100mg/mL pharmaceu...